Braftovi (encorafenib)

pCPA File Number: 21548

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic colorectal cancer (mCRC) in patients with a BRAF V600E mutation, as detected by a validated test, after prior therapy (in combination with cetuximab)

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

PC0233-000

pCPA Engagement Letter Issued:

2021-11-03

Negotiation Process Concluded:

2022-07-06